Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CABA logo CABA
Upturn stock rating
CABA logo

Cabaletta Bio Inc (CABA)

Upturn stock rating
$2.9
Last Close (24-hour delay)
Profit since last BUY51.83%
upturn advisory
Consider higher Upturn Star rating
BUY since 23 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

10/15/2025: CABA (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

12 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $12.25

1 Year Target Price $12.25

Analysts Price Target For last 52 week
$12.25 Target price
52w Low $0.99
Current$2.9
52w High $5.46

Analysis of Past Performance

Type Stock
Historic Profit -6.07%
Avg. Invested days 23
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulation Last Close 10/15/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 263.42M USD
Price to earnings Ratio -
1Y Target Price 12.25
Price to earnings Ratio -
1Y Target Price 12.25
Volume (30-day avg) 12
Beta 3.01
52 Weeks Range 0.99 - 5.46
Updated Date 10/16/2025
52 Weeks Range 0.99 - 5.46
Updated Date 10/16/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.71

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -42.39%
Return on Equity (TTM) -76.34%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 61618039
Price to Sales(TTM) -
Enterprise Value 61618039
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.44
Shares Outstanding 91465233
Shares Floating 61644823
Shares Outstanding 91465233
Shares Floating 61644823
Percent Insiders 1.65
Percent Institutions 79.77

ai summary icon Upturn AI SWOT

Cabaletta Bio Inc

stock logo

Company Overview

overview logo History and Background

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Founded in 2017, the company aims to develop targeted and selective therapies that can eliminate the underlying cause of these diseases.

business area logo Core Business Areas

  • Cell Therapy Development: Cabaletta Bio is focused on the development of targeted cell therapies, specifically Chimeric AutoAntibody Receptor (CAAR) T cells, designed to selectively eliminate pathogenic B cells.
  • Research and Discovery: The company is also engaged in ongoing research and discovery efforts to identify new targets and develop novel CAAR T-cell therapies for a range of autoimmune diseases.
  • Clinical Trials: Cabaletta Bio focuses on bringing CAAR-T cell therapies through clinical trials to demonstrate safety and efficacy.

leadership logo Leadership and Structure

Steven Nichtberger, M.D. serves as the Chief Executive Officer. The company has a board of directors and a management team with expertise in cell therapy, immunology, and drug development.

Top Products and Market Share

overview logo Key Offerings

  • Descartes-25: Descartes-25 (CD19-CAAR-T) is Cabaletta Biou2019s lead product candidate for the treatment of MuSK-associated myasthenia gravis (MG). No market share yet due to development stage. Competitors include pharmaceutical companies developing immunosuppressant drugs and other biologics for MG, such as argenx (ARGX) with Vyvgart.
  • Descartes-30: Descartes-30 (DSG3-CAAR-T) is being developed for the treatment of desmoglein 3 (DSG3)-positive pemphigus vulgaris (PV). No market share yet due to development stage. Competitors include pharmaceutical companies developing immunosuppressant drugs and biologics for PV, such as Roche (RHHBY) with Rituxan.

Market Dynamics

industry overview logo Industry Overview

The autoimmune disease market is a large and growing market with significant unmet medical needs. There is increasing interest in cell-based therapies and precision medicine approaches.

Positioning

Cabaletta Bio is positioned as a leader in the development of CAAR T-cell therapies for B cell-mediated autoimmune diseases. Its competitive advantage lies in its proprietary CAAR T-cell technology platform and its focus on highly specific targeting of pathogenic B cells.

Total Addressable Market (TAM)

The TAM for autoimmune disease therapies is substantial, estimated at tens of billions of dollars annually. Cabaletta Bio is positioned to address a subset of this market with its targeted cell therapies. The exact TAM specific to CAAR-T cell therapy is still evolving with clinical development and market acceptance. Cabaletta's strategy of targeting specific B-cell mediated autoimmune disorders allows them to focus their resources on areas of high unmet need.

Upturn SWOT Analysis

Strengths

  • Proprietary CAAR T-cell technology platform
  • Focus on highly specific targeting of pathogenic B cells
  • Experienced leadership team
  • Strong intellectual property position

Weaknesses

  • Clinical-stage company with no approved products
  • High risk associated with novel cell therapy development
  • Reliance on successful clinical trial outcomes
  • High cash burn rate

Opportunities

  • Expansion of CAAR T-cell technology to other autoimmune diseases
  • Potential for partnerships and collaborations
  • Breakthrough Therapy Designation and other regulatory incentives
  • Addressing unmet medical needs in specific autoimmune disorders

Threats

  • Clinical trial failures
  • Competition from other cell therapy companies
  • Regulatory hurdles and evolving guidelines
  • Manufacturing challenges and scalability

Competitors and Market Share

competitor logo Key Competitors

  • ARGX
  • RHHBY
  • JNJ
  • BMY

Competitive Landscape

Cabaletta Bio competes with established pharmaceutical companies and other biotechnology companies developing therapies for autoimmune diseases. Cabaletta's CAAR T-cell approach offers the potential for targeted and selective treatment, but faces challenges related to manufacturing and scalability compared to conventional drugs.

Growth Trajectory and Initiatives

Historical Growth: Cabaletta Bio's historical growth is characterized by the advancement of its CAAR T-cell therapy platform and the progress of its clinical trials.

Future Projections: Future growth depends on the successful completion of clinical trials, regulatory approvals, and commercialization of its products. Analyst estimates vary based on these factors.

Recent Initiatives: Recent initiatives include ongoing clinical trials for Descartes-25 and Descartes-30, as well as efforts to expand the CAAR T-cell platform to other autoimmune diseases.

Summary

Cabaletta Bio is a clinical-stage company with a promising CAAR T-cell technology platform targeting B cell-mediated autoimmune diseases. They have yet to bring a drug to market and their success depends on positive clinical trial outcomes. Key strengths include their innovative approach, but weaknesses include clinical trial risk and high cash burn. Potential threats are competition and regulatory hurdles. A solid cash position allows them to proceed with ongoing clinical trials.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Cabaletta Bio Inc. SEC Filings
  • Cabaletta Bio Inc. Investor Relations
  • Analyst Reports
  • Company Press Releases

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is based on estimates and may not be precise. All financial data is in USD unless otherwise stated.

Upturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Cabaletta Bio Inc

Exchange NASDAQ
Headquaters Philadelphia, PA, United States
IPO Launch date 2019-10-25
Co-Founder, Chairman, CEO & President Dr. Steven A. Nichtberger M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 167
Full time employees 167

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.